ARDELYX, INC. ARDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-2.34
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $407.3M | -$61.6M | — | -$44.0M | $166.9M |
| 2024 | $333.6M | -$39.1M | — | -$45.8M | $173.3M |
| 2023 | $124.5M | -$66.1M | — | -$90.1M | $166.8M |
| 2022 | $52.2M | -$67.2M | — | -$70.1M | $98.3M |
| 2021 | $10.1M | -$158.2M | — | -$154.4M | $82.6M |
| 2020 | $7.6M | -$94.3M | — | -$81.8M | $126.1M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -2.34 (distress)
- Working capital / assets 0.586
- Retained earnings / assets -1.888
- EBIT / assets -0.082
- Equity / liabilities 0.499
Source: SEC EDGAR filings · CIK 0001437402 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.